CGM-based Time-in-Range Using Insuln Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled in Range Trial
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
Den här webbplatsen innhåller information som endast är riktad till sjukvårdspersonal. Vänligen bekräfta nedan för att ta del av information, filmer, podcast och övrigt material.